June 30, 2025

Breakthrough Device Approvals Outpacing Data

Many FDA-authorized breakthrough therapeutic devices may lack robust clinical testing.

Conexiant

June 30, 2025

Can Typos Change a Diagnosis?

Large language models used in clinical decision-making may offer different treatment recommendations depending on how a patient writes their message—even when the medical facts remain unchanged.

Conexiant

June 27, 2025

Could Age Predict DVT in Cellulitis?

A 10-year study found that individuals aged 70 and above with lower limb cellulitis had significantly higher odds of developing deep vein thrombosis.

Conexiant

June 27, 2025

Gout and Ultrasound Predict Carotid Risk

Ultrasound features and gout flares help identify patients at risk for carotid plaque vulnerability, a key factor in stroke risk.

Conexiant

June 24, 2025

Cannabis Use Linked to Higher Heart Risks

A new systematic review and meta-analysis found that cannabis use is associated with an increased risk of major adverse cardiovascular events—including acute coronary syndrome, stroke, and cardiovascular death—based on data from more than 432 million individuals in 24 observational studies.

Conexiant

June 20, 2025

AI Screening Finds More Aneurysms In Breast MRI

An artificial intelligence system significantly increased detection of thoracic aortic aneurysms during routine breast MRI scans, identifying more cases than standard clinical readings.

Conexiant

June 19, 2025

Plaque Calcification May Predict Future Hemorrhage Risk

New research tracked subclinical carotid plaque changes over six years and found that plaques with calcification were twice as likely to develop intraplaque hemorrhage, with men showing greater risk for complex plaque progression.

Conexiant

June 19, 2025

Chronic Cannabis Use Linked to Vascular Impairment

A new cross-sectional study in healthy adults found that chronic marijuana smoking and edible THC use were linked to reduced endothelial function, an early marker of vascular disease risk.

Conexiant

June 16, 2025

Cytisinicline Shows Efficacy In Smoking Cessation Trial 

A phase 3 randomized clinical trial found that cytisinicline, a partial agonist at α4β2 nicotinic acetylcholine receptors, improved smoking cessation rates compared with placebo, with higher abstinence rates and reduced craving over 24 weeks.

Conexiant